Assessment of Troponin Levels as a Biomarker of Myocardial Injury in Patients with Fatal Covid-19 for the Period 2020 to 2022: A Literature Review
Background: COVID-19 initially described at the end of 2019. COVID-19 is caused by an uncommon coronavirus infection. Since then, it has been spreading rapidly and has caused a global pandemic, infecting more than 29 million people and causing more than 900,000 deaths as of September 15, 2020. In...
Saved in:
| Published in: | Kufa Journal for Nursing Sciences Vol. 14; no. 2; pp. 41 - 53 |
|---|---|
| Main Authors: | , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
28-08-2024
|
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Background: COVID-19 initially described at the end of 2019. COVID-19 is caused by an uncommon coronavirus infection. Since then, it has been spreading rapidly and has caused a global pandemic, infecting more than 29 million people and causing more than 900,000 deaths as of September 15, 2020. In most cases this disease mainly affects the respiratory system and can cause a syndrome called acute respiratory distress, leading to acute respiratory failure. However, COVID-19 causes other systemic indications, such as myocardial injury, coagulopathy, and cytokine storm. Myocardial injury patients were determined by elevated troponin levels by large number of COVID-19 patients, ranging from ''7.2% to 36%''. COVID-19 patients may experience myocardial injury due to other complications such as arrhythmias, heart failure, or even sudden cardiac arrest, as well, COVID-19 is a complex disease that can cause severe respiratory failure. Understanding these complications is crucial for managing the disease and developing effective treatment. Aim: This review research aims to assess the roles of troponin in COVID-19 patients at a higher risk of myocardial injury, as well as shed light on the most significant research articles conducted in this field of regard area between 2020 and 2022. Methods and Materials: This review outlined the latest scientific research for the period from 2020 to 2022 associated with the involvement of cardiac injury in the population of COVID-19 patients by focusing on the use of troponin levels as a vital indication. Additionally, it is starting from encountered patients with COVID-19, as well as it is related to the increased risk of death data and it had a crucial role in the identification of COVID-19 with a high risk of hypoxia in the blood. At that point, it was going through the evidence regarding COVID-19 and cardiovascular biomarkers, such as troponin articles recognized using the electronic search, as performed via PubMed, Embase, and Google Scholar Database through a comprehensive search conducted by combining key terms for instance; “biomarkers”, ’’myocarditis”, “COVID-19”, “troponin”. English-language articles were screened for relevance and a full review of publications for the important studies was conducted, including additional publications identified from individual article reference lists. Conclusion: Cardiac troponin (cTn) is the most reliable test for detecting heart disease, particularly myocardial injury. Elevated levels of troponin (both cTnI and cTnT) are a critical risk factor for severe myocardial injury and hospitalizations, especially for COVID-19 patients who face a higher risk of adverse events. Therefore, measuring cTn levels is critical to monitor the progression of heart disease and effectively manage patients' |
|---|---|
| ISSN: | 2223-4055 2521-8638 |
| DOI: | 10.36321/kjns.vi20242.16555 |